Insiders Who Sold Aroa Biosurgery Made The Right Call As Market Cap Slides By AU$33m

Simply Wall St.

Jan 31

By selling NZ$77k worth of Aroa Biosurgery Limited (ASX:ARX) stock at an average sell price of NZ$0.48 over the last year, insiders seemed to have made the most of their holdings. The company’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607075605"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607075605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607075605?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-31 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607075605","market":"nz","top_or_hot":-1,"title":"Insiders Who Sold Aroa Biosurgery Made The Right Call As Market Cap Slides By AU$33m","media":"Simply Wall St.","content":"<div>\n<p>By selling NZ$77k worth of Aroa Biosurgery Limited (ASX:ARX) stock at an average sell price of NZ$0.48 over the last year, insiders seemed to have made the most of their holdings.  The company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/insiders-who-sold-aroa-biosurgery-made-the-right-call-as-mar\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insiders Who Sold Aroa Biosurgery Made The Right Call As Market Cap Slides By AU$33m</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsiders Who Sold Aroa Biosurgery Made The Right Call As Market Cap Slides By AU$33m\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-31 06:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/insiders-who-sold-aroa-biosurgery-made-the-right-call-as-mar><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By selling NZ$77k worth of Aroa Biosurgery Limited (ASX:ARX) stock at an average sell price of NZ$0.48 over the last year, insiders seemed to have made the most of their holdings.  The company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/insiders-who-sold-aroa-biosurgery-made-the-right-call-as-mar\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/insiders-who-sold-aroa-biosurgery-made-the-right-call-as-mar","article_id":"2607075605","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/insiders-who-sold-aroa-biosurgery-made-the-right-call-as-mar","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607075605","pubTimestamp":1769813477,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"By selling NZ$77k worth of Aroa Biosurgery Limited ( ASX:ARX ) stock at an average sell price of NZ$0.48 over the last...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ARX.AU":"AROA BIOSURGERY LTD"},"translate_title":"随着市值下滑3300万澳元，出售Aroa Biosurgery的内部人士做出了正确的看涨期权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARX.AU":1},"content_text":"By selling NZ$77k worth of Aroa Biosurgery Limited (ASX:ARX) stock at an average sell price of NZ$0.48 over the last year, insiders seemed to have made the most of their holdings.  The company’s market cap plunged by AU$33m after price dropped by 13% last week but insiders were able to limit their loss to an extent.     Although we don't think shareholders should simply follow insider transactions,  logic dictates you should pay some attention to whether insiders are buying or selling shares.  AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.Advertisement The Last 12 Months Of Insider Transactions At Aroa Biosurgery   The Independent Non-Executive Director, John Diddams, made the biggest insider sale in the last 12 months. That single transaction was for AU$77k worth of shares at a price of AU$0.48 each.    That means that an insider was selling shares at  slightly  below the current price (AU$0.63).  When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation.  Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price.   This single sale was just 13% of John Diddams's stake.      John Diddams was the only individual insider to sell over the last year.     You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below.  By clicking on the graph below, you can see the precise details of each insider transaction!  View our latest analysis for Aroa Biosurgery ASX:ARX Insider Trading Volume January 30th 2026 If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.   Does Aroa Biosurgery Boast High Insider Ownership?  Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.  We usually like to see fairly high levels of insider ownership.   Aroa Biosurgery insiders own about AU$54m worth of shares. That equates to 25% of the company.  This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.   So What Does This Data Suggest About Aroa Biosurgery Insiders?  It doesn't really mean much that no insider has traded Aroa Biosurgery shares in the last quarter.      Our analysis of Aroa Biosurgery insider transactions leaves us cautious.   But we do like the fact that insiders own a fair chunk of the company.      If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.  If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}